GlaxoSmithKline Plc has shifted three candidate vaccines targeting filoviruses to the US non-profit organisation, the Sabin Vaccine Institute, as it restructurings its portfolio to put a bigger emphasis on oncology, HIV and respiratory diseases. The products are prophylactic vaccines to prevent infection from the Ebola Zaire, Ebola Sudan and Marburg viruses. They entered GSK’s portfolio when the UK company acquired Okairos AG in 2013.
